Google Ad

Piramal Pharma Solutions to amass G&W Laboratories’ drug manufacturing facility in US – Home Health Choices

New Delhi: Piramal Enterprises Ltd’s pharma options enterprise on Saturday stated it has entered right into a pact with G&W Laboratories Inc to amass its strong oral dosage drug product manufacturing facility at Sellersville in US for USD 17.5 million (over Rs 130 crore). “According to the terms of the agreement, Piramal Enterprises Ltd, through one of its affiliates, would acquire…100 per cent stake in the entity that operates the facility and owns the related real estate,” Piramal Pharma Solutions (PPS) stated in a press release.

This acquisition broadens the providing of Piramal Pharma Solutions by including strong oral dosage kind capabilities in North America. Until now, its capabilities in strong oral dosage kinds have been all positioned within the UK and India, it added.

“The Sellersville site can also produce liquids, creams, and ointments, further expanding the PPS portfolio,” the assertion stated.

The web site has acquired certifications from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), it added.

“Many of our customers are looking for US-based manufacturing partners to expand and support their pipeline. This acquisition strengthens our ability to partner with them on best-in-class drug products,” PPS CEO Peter DeYoung stated.

Piramal Pharma Solutions now affords strong oral drug product improvement and business manufacturing in all its main geographies, addressing a beforehand unmet buyer want and strengthening its means to work globally with prospects to scale back the burden of disease on sufferers, he added.

The firm expects to additional develop the positioning’s present energy to help improvement companies in addition to any COVID-19 administration drug alternatives, the assertion stated.

Latest Updates

Related Post